{
    "clinical_study": {
        "@rank": "134342", 
        "arm_group": {
            "arm_group_label": "NOMAC-E2 2.5 mg/1.5 mg", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day."
        }, 
        "brief_summary": {
            "textblock": "This study will investigate the efficacy and safety of the monophasic\n\n      combined oral contraceptive (COC) containing 2.5 mg NOMAC and 1.5 mg E2 in\n\n      healthy fertile Indian women."
        }, 
        "brief_title": "Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sexually active and at risk for pregnancy\n\n          -  Of Indian descent, born in India, never emigrated out of India, with Indian\n\n        home address\n\n          -  Body mass index (BMI) \u226517 and \u226435 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Presence or history of venous or arterial thrombotic/thromboembolic events\n\n        or cerebrovascular accident\n\n          -  Presence or history of prodromi of a thrombosis\n\n          -  History of migraine with focal neurological symptoms\n\n          -  Diabetes mellitus with vascular involvement\n\n          -  Presence of a severe or multiple risk factor(s) for venous or arterial\n\n        thrombosis\n\n          -  Severe hypertension\n\n          -  Severe dyslipoproteinemia\n\n          -  Presence or history of pancreatitis associated with severe\n\n        hypertriglyceridemia\n\n          -  Presence or history of severe hepatic disease\n\n          -  Undiagnosed vaginal bleeding\n\n          -  Known or suspected pregnancy\n\n          -  Currently breastfeeding or breastfeeding within 2 months of starting\n\n        trial medication\n\n          -  Investigational drug use or participation in another clinical trial within\n\n             2 months of signing Informed Consent Form for current trial"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723579", 
            "org_study_id": "P07057", 
            "secondary_id": "MK-8175A-017"
        }, 
        "intervention": [
            {
                "arm_group_label": "NOMAC-E2 2.5 mg/1.5 mg", 
                "description": "Oral tablet with daily release of 2.5 mg", 
                "intervention_name": "Nomegestrol acetate (NOMAC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NOMAC-E2 2.5 mg/1.5 mg", 
                "description": "Daily release of 1.5 mg", 
                "intervention_name": "Estradiol (E2)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Megestrol", 
                "Contraceptives, Oral", 
                "Contraceptives, Oral, Combined", 
                "Estradiol", 
                "Polyestradiol phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 21, 2013", 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multi-center Trial to Evaluate the Contraceptive Efficacy, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) in Indian Women. Protocol MK-8175A-017-00", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of In-treatment Pregnancies", 
            "safety_issue": "No", 
            "time_frame": "Day 1 of Treatment Cycle 1 Through Day 28 of Treatment Cycle 13, plus up to 2 additional days (Study Days 1-366)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants Experiencing an Adverse Event (AE) or Serious AE", 
            "safety_issue": "Yes", 
            "time_frame": "\"From Visit 1 up to 30 days after the last dose of study medication (up to Study Day 394)."
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}